

**Q2**

**2019  
RESULTS**



**OLIVIER BRANDICOURT**  
CHIEF EXECUTIVE OFFICER, SANOFI

**"Sanofi continued its growth phase with a solid business performance in the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and Emerging Markets"**

**COMPANY SALES & BUSINESS EPS\***

Q2 2019 SALES\*

**€8,628M**

+3.9% (+5.5%)

Q2 2019 BUSINESS EPS\*

**€1.31**

+4.8% (+4.8%)

\*Growth rates are expressed at constant exchange rates (CER). Growth rate in parentheses are expressed on a reported basis.

**SALES BY GLOBAL BUSINESS UNIT**

**€2,292M**



Sanofi Genzyme (Specialty Care)

**€2,281M**



Primary Care

**€1,891M**



China & Emerging Markets

**€1,143M**



Consumer Healthcare

**€1,021M**



Sanofi Pasteur (vaccines)

**SALES BY GEOGRAPHY**

\*Eurasia : Russia, Ukraine, Georgia, Belarus, Armenia and Turkey

\*\* Rest of the World : Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico.

- 1 U.S. €2,851M
- 2 EUROPE €2,164M
- 3 LATIN AMERICA €690M
- 4 EURASIA\* €322M
- 5 ASIA €1,132M
- 6 AFRICA & MIDDLE EAST €553M

ROW\*\* €889M



**FOR FURTHER INFORMATION ON Q2 2019 RESULTS AND DEFINITIONS OF FINANCIAL INDICATORS, PLEASE REFER TO THE PRESS RELEASE ISSUED ON JULY 29, 2019 AT:**

[HTTPS://WWW.SANOFI.COM/EN/INVESTORS](https://www.sanofi.com/en/investors)

SANOFI.COM

SANOFI.US



@Sanofi



Sanofi



@Sanofi



@SanofiUS



SanofiUS